Literature DB >> 24941292

Protective effect of Acacia ferruginea against ulcerative colitis via modulating inflammatory mediators, cytokine profile and NF-κB signal transduction pathways.

Kunnathur Murugesan Sakthivel1, Chandrasekaran Guruvayoorappan2.   

Abstract

In the present study, we evaluated the protective effect of A. ferruginea extract against ulcerative colitis (UC). Male Wistar rats received A. ferruginea extract (10 mg/kg body weight) or sulfasalazine (100 mg/kg body weight) for 5 consecutive days before inducing UC via intrarectal acetic acid (3%) administration. Colonic mucosal injury was assessed by macroscopic scoring, vascular permeability testing, and histopathological examination. The mucosal contents of glutathione, lipid peroxidation, superoxide dismutase, and nitric oxide were evaluated as parameters for the redox state. Inflammatory response was determined by measuring inducible nitric oxide synthase (iNOS) and cyclo-oxygenase (COX-2) expression. Myeloperoxidase (MPO), lactate dehydrogenase assay (LDH), tumor necrosis factor (TNF-α), and interleukins (IL-1β and IL-6) were measured using ELISA. Transcription factor profiling of nuclear factor (NF)-κB subunits (p65/p50) was also conducted using ELISA. All of the relevant parameters were altered in rats with UC, and these parameters improved in animals that received A. ferruginea extract. Colonic mucosal injury parallels antioxidant and anti-inflammatory evaluations, and A. ferruginea extract was considered comparable to the standard treatment drug sulfasalazine. Histopathological studies confirmed these findings. A. ferruginea extract inhibited the activation and translocation of transcription factors, that is, NF-κB subunits (p65/p50). The results of our investigation clearly indicate that treatment with A. ferruginea extract exerted a marked protective effect against experimental UC via modulation of oxidant/anti-oxidant balance and inhibition of inflammatory mediators.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24941292     DOI: 10.1615/jenvironpatholtoxicoloncol.2014008425

Source DB:  PubMed          Journal:  J Environ Pathol Toxicol Oncol        ISSN: 0731-8898            Impact factor:   3.567


  10 in total

1.  Intraperitoneal administration of butyrate prevents the severity of acetic acid colitis in rats.

Authors:  Joshua J Malago; Catherine L Sangu
Journal:  J Zhejiang Univ Sci B       Date:  2015-03       Impact factor: 3.066

2.  An immuno-blocking agent targeting IL-1β and IL-17A reduces the lesion of DSS-induced ulcerative colitis in mice.

Authors:  Qi Yin; Xuelei Pi; Yuanyuan Jiang; Guiping Ren; Zhihang Liu; Han Liu; Mengxia Wang; Wenying Sun; Siyu Li; Zhenqiu Gao; Deshan Li; Jiechao Yin
Journal:  Inflammation       Date:  2021-04-20       Impact factor: 4.092

3.  Anti-inflammatory effects of acacia and guar gum in 5-amino salicylic acid formulations in experimental colitis.

Authors:  Henusha D Jhundoo; Tobias Siefen; Alfred Liang; Christoph Schmidt; John Lokhnauth; Brice Moulari; Arnaud Béduneau; Yann Pellequer; Crilles Casper Larsen; Alf Lamprecht
Journal:  Int J Pharm X       Date:  2021-04-24

4.  Naringenin inhibits migration of breast cancer cells via inflammatory and apoptosis cell signaling pathways.

Authors:  Zhenjiang Zhao; Guoguo Jin; Yinghui Ge; Zhiping Guo
Journal:  Inflammopharmacology       Date:  2019-04-02       Impact factor: 5.093

5.  A New Chinese Medicine Intestine Formula Greatly Improves the Effect of Aminosalicylate on Ulcerative Colitis.

Authors:  Baohai Liu; Xuehua Piao; Lianyi Guo; Guijun Wang; Weihua Sun; Leming Gao; Xuefeng Zheng; Yanli Fang
Journal:  Evid Based Complement Alternat Med       Date:  2017-11-20       Impact factor: 2.629

Review 6.  Pathomechanisms of Oxidative Stress in Inflammatory Bowel Disease and Potential Antioxidant Therapies.

Authors:  Tian Tian; Ziling Wang; Jinhua Zhang
Journal:  Oxid Med Cell Longev       Date:  2017-06-28       Impact factor: 6.543

Review 7.  Implications of Antioxidant Systems in Inflammatory Bowel Disease.

Authors:  Guiping Guan; Shile Lan
Journal:  Biomed Res Int       Date:  2018-05-09       Impact factor: 3.411

Review 8.  Targeting NF-κB pathway for treating ulcerative colitis: comprehensive regulatory characteristics of Chinese medicines.

Authors:  Peng-De Lu; Yong-Hua Zhao
Journal:  Chin Med       Date:  2020-02-10       Impact factor: 5.455

Review 9.  Antioxidant therapy for treatment of inflammatory bowel disease: Does it work?

Authors:  Fabiana Andréa Moura; Kívia Queiroz de Andrade; Juliana Célia Farias Dos Santos; Orlando Roberto Pimentel Araújo; Marília Oliveira Fonseca Goulart
Journal:  Redox Biol       Date:  2015-10-23       Impact factor: 11.799

10.  Tryptanthrin Protects Mice against Dextran Sulfate Sodium-Induced Colitis through Inhibition of TNF-α/NF-κB and IL-6/STAT3 Pathways.

Authors:  Zheng Wang; Xue Wu; Cui-Ling Wang; Li Wang; Chen Sun; Dong-Bo Zhang; Jian-Li Liu; Yan-Ni Liang; Dong-Xin Tang; Zhi-Shu Tang
Journal:  Molecules       Date:  2018-05-02       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.